

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

(REV. 7-80)

LIST OF REFERENCES CITED BY APPLICANT

(Use Several Sheets if Necessary)

DOCKET NO.: 5432/0J951US0

SERIAL NO.: TBA (Continuation of PCT/DK00/00377)

APPLICANT: Connie SANCHEZ and Sandra HOGG

FILING DATE: Concurrently Herewith

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
FL 1.	5,296,507	3/22/94	Tanaka et al.	514	465	
FL 2.	4,943,590	7/24/90	Boegesoe et al.	514	469	

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
FL 3.	0034263	6/15/00	WO	C07D	307/87	
FL 4.	0015220	3/23/00	WO	A61K	31/35	

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

- FL 5. A.F. Joubert et al., "Citalopram and Anxiety Disorders," *Rev. Contemp. Pharmacother* 10: 79-131 (1999)
- FL 6. Ulla M. Lepola et al., "A Controlled, Perspective, 1-Year Trial of Citalopram in the Treatment of Panic Disorder," *J. Clin. Psychiatry* 59, 10: 528-534 (1998)
- FL 7. H. Koponen et al., "Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study," *Acta Psychiatrica Scandinavica* 96: 343-346 (1997)
- FL 8. Dan J. Stein et al., "Use of serotonin selective reuptake inhibitor citalopram in obsessive-compulsive disorder," *Journal of Serotonin Research* 1: 29-33 (1996)

EXAMINER
INITIALS

EXAMINER:

Krass

DATE CONSIDERED:

05/03

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

SHEET 1 OF 1
(REV. 7-80)**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 5432/OJ951US0
APPLICANT: SANCHEZ et al.SERIAL NO: 10/021,126
FILING DATE: Dec. 12, 2001
CONFIRMATION NO: 7268**U.S. PATENT DOCUMENTS**

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>NAME</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>FILING DATE</u>
FL	1. 4,650,884	3/17/87	Bogeso	549	467	8/2/85
FL	2. 4,136,193	1/23/79	Bogeso et al.	424	285	1/7/77
FL	3. 3,467,675	9/16/69	Petersen et al.	260	346.2	3/3/66

FOREIGN PATENT DOCUMENTS

<u>*EXAMINER INITIALS</u>	<u>DOCUMENT NUMBER</u>	<u>DATE</u>	<u>COUNTRY</u>	<u>CLASS</u>	<u>SUBCLASS</u>	<u>TRANSLATION</u> <u>YES</u> <u>NO</u>
-------------------------------	----------------------------	-------------	----------------	--------------	-----------------	--

OTHER REFERENCES**(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)***EXAMINER
INITIALS

FL 4. Bigler, Allan et al., "Quantitative Structure-activity Relationships in a Series of Selective 5-HT uptake inhibitors, "Eur. J. Med. Chem. 3:289-295 (1997)

EXAMINER: KrassDATE CONSIDERED: 05/03*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number 10/021,126
Filing Date December 12, 2001
First Named Inventor Connie SANCHEZ
Group Art Unit 1614
Examiner Name Frederick R. KRASS
Attorney Docket Number 5432/OJ951/USO

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
FL	1.	US-6,469,064 B2	10/22/02	Druzgala	
	2.	US- 6,333,357 B1	12/25/01	Eig	
	3.	US- 6,159,971	12/12/00	Berg et al.	
	4.	US- 6,147,072	11/14/00	Bymaster et al.	
	5.	US- 6,069,177	5/30/00	Carlier et al.	
	6.	US- 5,962,514	10/5/99	Evenden et al.	
	7.	US- 5,958,429	9/28/99	Wong	
	8.	US- 5,788,986	8/4/98	Dodman	
	9.	US- 5,648,396	7/15/97	Young et al.	
	10.	US- 5,114,976	5/19/92	Norden	
	11.	US- 4,962,128	10/9/90	Doogan et al.	
	12.	US- 4,902,710	2/20/90	Foster et al.	

RECEIVED
TECH CENTER 1600/2900
03 MAR - 3 PM 3:22

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
FL	13.	WO 01/54681 A2	8/2/01	Massachusetts Institute of Technology		
	14.	WO 00/15220	3/23/00	Astra Aktiebolag		
	15.	WO 00/15219	3/23/00	Astra Aktiebolag		
	16.	WO 00/03701	1/27/00	Massachusetts Institute of Technology		
	17.	WO 00/02551	1/20/00	NPS Pharmaceutical, Inc.		
	18.	EP 0 759 299	2/26/97	Eli Lilly and Company		
	19.	EP 0 714 663 A2	6/5/96	Eli Lilly and Company		
	20.	WO 93/09769	5/27/93	Sepracor, Inc.		
	21.	WO 92/18005	10/29/92	National Institutes of Health		

RECEIVED
MAR 03 2003
TECH CENTER 1600/2900

Examiner Signature	Krass	Date Considered	05/03
-----------------------	-------	--------------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/021,126
Filing Date	December 12, 2001
First Named Inventor	Connie SANCHEZ
Group Art Unit	1614
Examiner Name	Frederick R. KRASS
Attorney Docket Number	5432/OJ951US0

RECEIVED

MAR 05 2003

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
FR	22.	Soraya Seedat et al., "Open trial of citalopram in adults with post-traumatic stress disorder," International Journal of Neuropsychopharmacology 3: 135-140 (2000)	
	23.	Ihoko Muraki et al., "Effect of subchronic lithium carbonate treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat," European Journal of Pharmacology 383: 223-229 (1999)	
	24.	Jennifer Y. Tan et al., "Citalopram in the Treatment of Depression and Other Potential Uses in Psychiatry," Pharmacotherapy 19, 6: 675-689 (1999)	
	25.	Mario Amore et al., "Short-Term and Long-Term Evaluation of Selective Serotonin Reuptake Inhibitors in the Treatment of Panic Disorder: Fluoxetine vs Citalopram," Hum. Psychopharmacol. Clin. Exp. 14: 435-440 (1999)	
	26.	Emanuela Mundo, M.D. et al., "Efficacy of Fluvoxamine, Paroxetine, and Citalopram in the Treatment of Obsessive-Compulsive Disorder: A Single-Blind Study," Journal of Clinical Psychopharmacology 17, 4: 267-271 (August 1997)	
	27.	Zoltan Rihmer, "Successful treatment of salbutamol-induced panic disorder with citalopram," European Neuropsychopharmacology 7: 241-242 (1997)	
	28.	Takeshi Inoue et al., "Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing," European Journal of Pharmacology 311: 1-6 (1996)	
	29.	U. Lepola et al., "Citalopram in the Treatment of Early-onset Panic Disorder and School Phobia," Pharmacopsychiatry 29: 30-32 (January 1996)	
	30.	J. Hyttel et al., "The Pharmacology of Citalopram," Rev. Contemp. Pharmacother. 6: 271-285 (1995)	
FR	31	American Psychiatric Association, "DSM-IV" (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition): 393-444 (1994)	

Examiner
Signature

Krass

Date
Considered

05/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.